Skip to Main Content

Author Details

Laura J Van't Veer
University of California San Francisco
1984
351
93
Trey Ideker (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36759733A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF<sup>V600E</sup> colorectal tumors.Nat Cancer2023
38086377Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial.Cell Rep Med2023
37794508B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer.Breast Cancer Res2023
37479706Obesity-associated changes in molecular biology of primary breast cancer.Nat Commun2023
37738542Characterization of the Tumor Microenvironment of De Novo Oligometastatic Breast Cancer in a Nationwide Cohort.JCO Precis Oncol2023
37607323Early Ascertainment of Breast Cancer Diagnoses Comparing Self-Reported Questionnaires and Electronic Health Record Data Warehouse: The WISDOM Study.JCO Clin Cancer Inform2023
37384294Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes.Front Oncol2023
37146605Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.Cancer Cell2023
36997615Radiomic tumor phenotypes augment molecular profiling in predicting recurrence free survival after breast neoadjuvant chemotherapy.Commun Med (Lond)2023
37029329Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial.Breast Cancer Res Treat2023
36689693Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival.J Clin Oncol2023
36689092Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study.Breast Cancer Res Treat2023
36681803Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance.Mol Cancer2023
34843026A case-case analysis of women with breast cancer: predictors of interval vs screen-detected cancer.Breast Cancer Res Treat2022
35372077Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy.Front Oncol2022
35666959Biomarkers for Cyclin-Dependent Kinase 4/6 Inhibitors in the Treatment of Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced/Metastatic Breast Cancer: Translation to Clinical Practice.JCO Precis Oncol2022
35862873Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial.J Clin Oncol2022
35623341Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.Cancer Cell2022
35513244Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials.Ann Oncol2022
36456573Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.NPJ Breast Cancer2022
36414627Author Correction: Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer.Nat Commun2022
36139594Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy.Cancers (Basel)2022
36126477Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancer.Eur J Cancer2022
34861376Outcome without any adjuvant systemic treatment in stage I ER+/HER2- breast cancer patients included in the MINDACT trial.Ann Oncol2022
35179782Clinical and molecular characteristics of estrogen receptor-positive ultralow risk breast cancer tumors identified by the 70-gene signature.Int J Cancer2022
35061525Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial.J Clin Oncol2022
34902335Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.Lancet Oncol2022
33399073A clinical validation study of MammaPrint in hormone receptor-positive breast cancer from the Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG-8) biomarker cohort.ESMO Open2021
33767190Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk.NPJ Breast Cancer2021
33621798Contralateral prophylactic mastectomy: A narrative review of the evidence and acceptability.Breast2021
33648460Toward developing a metastatic breast cancer treatment strategy that incorporates history of response to previous treatments.BMC Cancer2021
33617937Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy.Ann Oncol2021
3372156170-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.Lancet Oncol2021
34934058The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study.NPJ Breast Cancer2021
34591612A protein interaction landscape of breast cancer.Science2021
34529196The WISDOM study: a new approach to screening can and should be tested.Breast Cancer Res Treat2021
34529000Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.JAMA Oncol2021
34611148Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.NPJ Breast Cancer2021
34508103Circadian PERformance in breast cancer: a germline and somatic genetic study of PER3<sup>VNTR</sup> polymorphisms and gene co-expression.NPJ Breast Cancer2021
34741023Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2<sup>+</sup> breast cancer in the adaptively randomized I-SPY2 trial.Nat Commun2021
34741021RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer.Nat Commun2021
34344894Elevated risk thresholds predict endocrine risk-reducing medication use in the Athena screening registry.NPJ Breast Cancer2021
34095775PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial.JAMIA Open2021
33957704Incorporation of Patient-Reported Outcomes Measurement Information System to assess quality of life among patients with breast cancer initiating care at an academic center.Cancer2021
34143979Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.Cancer Cell2021
33977227Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer.JNCI Cancer Spectr2021
34191200Combining method of detection and 70-gene signature for enhanced prognostication of breast cancer.Breast Cancer Res Treat2021
32527022Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy.Cancers (Basel)2020
32031889MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.J Clin Oncol2020
32083990Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial.J Clin Oncol2020
  • 1 - 50 of 351

Recommended Authors

Martin Sj??str??m
University of California-San Francisco
Career Start Year 2013
Number of shared co-authors 6
Hans Kristian Moen Vollan
F Hoffmann-La Roche Ltd
Career Start Year 2010
Number of shared co-authors 30
Charlotte K Y Ng
University of Bern
Career Start Year 2009
Number of shared co-authors 29
Melanie Spears
Ontario Institute for Cancer Research
Career Start Year 2008
Number of shared co-authors 2
Carmen Criscitiello
University of Milano
Career Start Year 2008
Number of shared co-authors 9
Eric C Polley
Mayo Clinic
Career Start Year 2007
Number of shared co-authors 49
Samuel Leung
University of British Columbia
Career Start Year 2007
Number of shared co-authors 63
Nicola Waddell
QIMR Berghofer Medical Research Institute
Career Start Year 2006
Number of shared co-authors 60
Catherine M Kelly
Mater Misericordiae University Hospital
Career Start Year 2006
Number of shared co-authors 22
Caterina Marchi??
University of Turin, Candiolo Cancer Institute, FPO-IRCCS
Career Start Year 2005
Number of shared co-authors 8
David W Cescon
Princess Margaret Cancer Centre
Career Start Year 2003
Number of shared co-authors 13
Karin Jirstr??m
Lund University
Career Start Year 2003
Number of shared co-authors 11
Nicola Fusco
IEO European Institute of Oncology IRCCS
Career Start Year 2002
Number of shared co-authors 6
Siddhartha Deb
Olivia Newton-John Cancer Research Institute
Career Start Year 2002
Number of shared co-authors 2
Joel S Parker
Lineberger Cancer Center, University of North Carolina
Career Start Year 2002
Number of shared co-authors 40
Darran P O'Connor
UCD Conway Institute, University College Dublin
Career Start Year 2001
Number of shared co-authors 10
Loris De Cecco
Fondazione IRCCS Istituto Nazionale dei Tumori
Career Start Year 2000
Number of shared co-authors 4
Massimo Cristofanilli
Weill Cornell School of Medicine
Career Start Year 1998
Number of shared co-authors 21
Ingrid Hedenfalk
Lund University and Skane University Hospital
Career Start Year 1997
Number of shared co-authors 33
Jan Budczies
Institute of Pathology, University Hospital Heidelberg
Career Start Year 1996
Number of shared co-authors 6
William M Gallagher
All-Island Cancer Research Institute, UCD Conway Institute, University College Dublin
Career Start Year 1996
Number of shared co-authors 21
Susan J Done
University Health Network
Career Start Year 1994
Number of shared co-authors 5
Maria Aparecida Azevedo Koike Folgueira
Center for Translational Oncology, Cancer Institute of the State of Sao Paulo - ICESP
Career Start Year 1993
Number of shared co-authors 2
Peggy L Porter
Fred Hutchinson Cancer Research Center
Career Start Year 1991
Number of shared co-authors 28
Ben Ho Park
Vanderbilt University Medical Center
Career Start Year 1990
Number of shared co-authors 23
Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center
Career Start Year 1990
Number of shared co-authors 36
Paul J van Diest
University Medical Center Utrecht
Career Start Year 1989
Number of shared co-authors 35
Olli Kallioniemi
Karolinska Institute
Career Start Year 1984
Number of shared co-authors 29
Edison T Liu
USA The Jackson Laboratory Cancer Center
Career Start Year 1982
Number of shared co-authors 14
Jeffrey S Ross
Foundation Medicine
Career Start Year 1974
Number of shared co-authors 13

Collaborators

Christina Yau
University of California San Francisco
Co-authored papers 46
Denise M Wolf
University of California San Francisco
Co-authored papers 39
Douglas F Easton
University of Cambridge
Co-authored papers 35
Fatima Cardoso
Champalimaud Clinical Center/Champalimaud Foundation
Co-authored papers 33
Paul D P Pharoah
Center for Cancer Genetic Epidemiology, University of Cambridge
Co-authored papers 32
Fergus J Couch
Mayo Clinic
Co-authored papers 29
Jenny Chang-Claude
German Cancer Research Center (DKFZ)
Co-authored papers 28
Montserrat Garcia-Closas
National Cancer Institute
Co-authored papers 28
Graham G Giles
Co-authored papers 28
Peter A Fasching
Otto-Friedrich-University Bamberg
Co-authored papers 27
Alison M Dunning
Co-authored papers 27
Javier Ben??tez
Instituto de Salud Carlos III
Co-authored papers 26
Per Hall
Co-authored papers 26
Caroline Seynaeve
Erasmus Medical Center
Co-authored papers 26
Hoda Anton-Culver
University of California irvine
Co-authored papers 25
Roger L Milne
Co-authored papers 25
Georgia Chenevix-Trench
QIMR Berghofer Medical Research Institute
Co-authored papers 25
Irene L Andrulis
University of Toronto
Co-authored papers 24
Diether Lambrechts
Co-authored papers 24
Janet E Olson
Mayo Clinic
Co-authored papers 23
Lodewyk F A Wessels
University Medical Centre Mannheim, University of Heidelberg
Co-authored papers 23
Claudine Isaacs
Co-authored papers 23
Børge G Nordestgaard
Co-authored papers 23
Jonine D Figueroa
The Usher Institute, The University of Edinburgh
Co-authored papers 22
Jolanta Lissowska
The M. Sklodowska-Curie Cancer Center and Institute of Oncology
Co-authored papers 22
Stephen J Chanock
National Cancer Institute, National Institutes of Health
Co-authored papers 21
William F Symmans
Co-authored papers 21
Donald A Berry
MD Anderson Cancer Center
Co-authored papers 20
Julia A Knight
Co-authored papers 20
Christopher A Haiman
University of Southern California
Co-authored papers 19
Release 1.2